SpringWorks Therapeutics announced that the U.S. FDA has approved OGSIVEO, an oral gamma secretase inhibitor, for the treatment of adult patients with progressing desmoid tumors who require systemic treatment. The FDA previously granted breakthrough therapy, fast track and orphan drug designations to nirogacestat for the treatment of desmoid tumors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SWTX:
- SpringWorks Stock (NASDAQ:SWTX) Rallies on FDA’s Rare Tumor Drug Approval
- SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors
- SpringWorks Therapeutics price target raised to $58 from $55 at JPMorgan
- SpringWorks price target lowered to $52 from $58 at H.C. Wainwright
- SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN